HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintains a $48 price target.
February 28, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Pliant Therapeutics with a $48 price target.
The reiteration of a Buy rating and maintenance of a $48 price target by a reputable analyst could positively influence investor sentiment towards PLRX, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100